- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07939529
People With Active Viremia Treated With Lenacapavir and Long-Acting Cabotegravir for Effectiveness (PALACE)
This pilot, single-arm, open-label study conducted in the United States will evaluate the efficacy, safety, tolerability, and pharmacokinetics of long-acting lenacapavir plus cabotegravir (LA LEN+CAB) in people with HIV-1 viremia who have a history of non-adherence and confirmed or suspected rilpivirine (RPV) resistance. Participants will be on study for up to 108 weeks.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
Alabama
-
Birmingham, Alabama, Förenta staterna, 35222
- Alabama (Site ID: 31788)
-
Kontakt:
- Heather Logan
- Telefonnummer: 205-934-6774
- E-post: heatherlogan@uabmc.edu
-
-
California
-
Los Angeles, California, Förenta staterna, 90035
- University of California, Los Angeles CARE Center (Site ID: 601)
-
Kontakt:
- Aleen Khodabakhshian
- Telefonnummer: 310-557-3798
- E-post: akhodabakhshian@mednet.ucla.edu
-
San Diego, California, Förenta staterna, 92103
- UCSD Antiviral Research Center (Site ID: 701)
-
Kontakt:
- Dawn Rosenblum
- Telefonnummer: 619-543-8080
- E-post: drosenblum@health.ucsd.edu
-
San Francisco, California, Förenta staterna, 94110
- University of California, San Francisco (Site ID: 801)
-
Kontakt:
- Jay Dwyer
- Telefonnummer: 415-502-5748
- E-post: jay.dwyer@ucsf.edu
-
Torrance, California, Förenta staterna, 90502-2052
- Harbor University of California Los Angeles Center (Site ID: 603)
-
Kontakt:
- Mario Guerrero
- Telefonnummer: 323-457-1459
- E-post: mguerrero@lundquist.org
-
-
Colorado
-
Aurora, Colorado, Förenta staterna, 80045
- University of Colorado Hospital (Site ID: 6101)
-
Kontakt:
- Nicola Haakonsen
- Telefonnummer: 303-724-5931
- E-post: nicola.haakonsen@cuanschutz.edu
-
-
District of Columbia
-
Washington D.C., District of Columbia, Förenta staterna, 20032
- Whitman-Walker Institute, Inc. (Site ID: 21791)
-
Kontakt:
- Avery Wimpelberg
- Telefonnummer: 202-797-3589
- E-post: awimpelberg@whitman-walker.org
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60611
- Northwestern University (Site ID: 2701)
-
Kontakt:
- Sherryl L Wolfe
- Telefonnummer: 312-695-4997
- E-post: s-wolfe@northwestern.edu
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21287
- Johns Hopkins University (Site ID: 201)
-
Kontakt:
- Rebecca L Becker
- Telefonnummer: 410-614-4036
- E-post: rbecke22@jhmi.edu
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02114
- Massachusetts General Hospital (Site ID: 101)
-
Kontakt:
- Amy Sbrolla
- Telefonnummer: 617-726-5598
- E-post: asbrolla@mgh.harvard.edu
-
Boston, Massachusetts, Förenta staterna, 02115
- Brigham and Women's Hospital Therapeutics (BWH TCRS) (Site ID: 107)
-
Kontakt:
- Hannah Jordan
- Telefonnummer: 617-732-4785
- E-post: hcjordan@bwh.harvard.edu
-
-
New Jersey
-
Newark, New Jersey, Förenta staterna, 07103
- New Jersey Medical School Clinical Research Center (Site ID: 31786)
-
Kontakt:
- Christie Lyn Costanza
- Telefonnummer: 972-972-9069
- E-post: costancl@njms.rutgers.edu
-
-
New York
-
New York, New York, Förenta staterna, 10010
- Weill Cornell Chelsea (Site ID: 7804)
-
Kontakt:
- Mauricio Vergara
- Telefonnummer: 212-746-7204
- E-post: mav9177@med.cornell.edu
-
New York, New York, Förenta staterna, 10010
- Weill Cornell Uptown (Site ID: 7803)
-
Kontakt:
- Keisha Ballentine-Cargill
- Telefonnummer: 212-746-7804
- E-post: keb4006@med.cornell.edu
-
New York, New York, Förenta staterna, 10032
- Columbia Physicians & Surgeons (P&S) (Site ID: 30329)
-
Kontakt:
- Brett T Gray
- Telefonnummer: 212-305-1570
- E-post: bg2168@cumc.columbia.edu
-
-
North Carolina
-
Chapel Hill, North Carolina, Förenta staterna, 27599-7215
- Chapel Hill (Site ID: 3201)
-
Kontakt:
- Erin Elizabeth Hoffman
- Telefonnummer: 919-843-0720
- E-post: erin_hoffman@med.unc.edu
-
Greensboro, North Carolina, Förenta staterna, 27401-1020
- Greensboro (Site ID: 3203)
-
Kontakt:
- Kelly Phillips
- Telefonnummer: 336-832-7297
- E-post: kelly.phillips@conehealth.com
-
-
Ohio
-
Cincinnati, Ohio, Förenta staterna, 45267-0405
- Cincinnati Clinical Research Site (Site ID: 2401)
-
Kontakt:
- Michelle Saemann
- Telefonnummer: 513-584-2245
- E-post: saemanmd@ucmail.uc.edu
-
Cleveland, Ohio, Förenta staterna, 44106
- Case Clinical Research Site (Site ID: 2501)
-
Kontakt:
- Julie Pasternak
- Telefonnummer: 216-844-2738
- E-post: pasternak.julie@clevelandactu.org
-
Columbus, Ohio, Förenta staterna, 43210
- Ohio State University (Site ID: 2301)
-
Kontakt:
- Lindsay Summers
- Telefonnummer: 614-293-8529
- E-post: lindsay.summers@osumc.edu
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Förenta staterna, 15213
- University of Pittsburgh (Site ID: 1001)
-
Kontakt:
- Stacey Edick
- Telefonnummer: 412-383-1748
- E-post: edicksm2@upmc.edu
-
-
Tennessee
-
Nashville, Tennessee, Förenta staterna, 37204
- Vanderbilt Therapeutics (VT) (Site ID: 3652)
-
Kontakt:
- Beverly Woodward
- Telefonnummer: 615-936-8516
- E-post: beverly.o.woodward@vumc.org
-
-
Texas
-
Houston, Texas, Förenta staterna, 77030
- Houston Advancing Research Team (Site ID: 31473)
-
Kontakt:
- Maria Laura Martinez
- Telefonnummer: 713-500-6718
- E-post: maria.l.martinez@uth.tmc.edu
-
-
Washington
-
Seattle, Washington, Förenta staterna, 98104
- University of Washington Positive Research (Site ID: 1401)
-
Kontakt:
- Allysson Angeldekao
- Telefonnummer: 503-715-7324
- E-post: allysson@uw.edu
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
-
Documented HIV-1 infection
-
Prior antiretroviral therapy (ART) experience, including having first been prescribed ART at least 24 weeks prior to enrollment and self-report of prior oral ART use
-
HIV-1 RNA >1000 copies/mL within 60 days prior to study entry
-
Evidence of non-adherence to ART, including virologic failure, poor virologic response, or loss to clinical follow-up with ART non-use/non-adherence
-
At least one reason why NNRTI-based ART is clinically inappropriate, including documented or suspected rilpivirine resistance or prior rilpivirine intolerance
-
Adequate laboratory parameters within 60 days prior to study entry:
- Absolute neutrophil count >600/mm3
- Hemoglobin ≥7.0 g/dL
- Platelet count >50,000/μL
- AST and ALT ≤3 × upper limit of normal
- Estimated glomerular filtration rate >15 mL/min/1.73 m²
-
For participants of childbearing potential, negative pregnancy test at screening and within 24 hours prior to study entry
-
Ability and willingness to provide informed consent
-
Connected to a medical clinic with access to HIV care and antiretroviral therapy
Exclusion Criteria:
- Documented integrase strand transfer inhibitor (INSTI) resistance-associated mutations that may compromise cabotegravir activity
- Active hepatitis B infection, defined as positive hepatitis B surface antigen or detectable hepatitis B virus DNA
- Child-Pugh Class C cirrhosis
- No suitable injection site for cabotegravir administration due to implants, tattoos, or skin conditions interfering with injection site assessment
- Prior use of lenacapavir
- Receipt of HIV immunotherapeutic vaccines or HIV monoclonal antibodies within 6 months prior to study entry
- Serious medical or psychiatric condition
- Use of prohibited concomitant medications with lenacapavir or cabotegravir within 30 days prior to study entry
- Current pregnancy or breastfeeding
- Known allergy, hypersensitivity, or intolerance to cabotegravir, lenacapavir, or formulation components
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Long-Acting Lenacapavir Plus Long-Acting Cabotegravir
|
Long-acting subcutaneous lenacapavir administered every 24 weeks with oral loading doses at treatment initiation. Long-acting intramuscular cabotegravir administered every 8 weeks following initiation doses. Oral antiretroviral therapy provided as bridge therapy during interruptions or delays in long-acting treatment. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Proportion of participants achieving and maintaining viral suppression (no confirmed virologic failure) while receiving long-acting lenacapavir plus cabotegravir
Tidsram: Baseline through Week 48
|
Baseline through Week 48
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Proportion of participants with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
Tidsram: Week 48
|
Week 48
|
|
|
Proportion of participants with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
Tidsram: Week 48
|
Week 48
|
|
|
Proportion of participants with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
Tidsram: Week 48
|
Week 48
|
|
|
Proportion of participants with Grade 3 or higher adverse events related to long-acting lenacapavir plus cabotegravir
Tidsram: Baseline through Week 96
|
Baseline through Week 96
|
|
|
Proportion of participants discontinuing long-acting lenacapavir plus cabotegravir due to adverse events or intolerance
Tidsram: Baseline through Week 96
|
Baseline through Week 96
|
|
|
Proportion of participants achieving and maintaining viral suppression without confirmed virologic failure on long-acting lenacapavir plus cabotegravir
Tidsram: Baseline through Week 96
|
Baseline through Week 96
|
|
|
Proportion of participants with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
Tidsram: Week 96
|
Week 96
|
|
|
Proportion of participants with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
Tidsram: Week 96
|
Week 96
|
|
|
Proportion of participants with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
Tidsram: Week 96
|
Week 96
|
|
|
Percentage of on-time long-acting injections
Tidsram: Through Week 48 and through Week 96
|
Through Week 48 and through Week 96
|
|
|
Proportion of participants discontinuing long-acting lenacapavir plus cabotegravir
Tidsram: Baseline through Week 48 and through Week 96
|
Baseline through Week 48 and through Week 96
|
|
|
Plasma trough concentrations of lenacapavir and cabotegravir
Tidsram: Through Week 48 and through Week 96
|
Through Week 48 and through Week 96
|
|
|
Change in CD4 cell count from baseline
Tidsram: Week 48 and Week 96
|
Week 48 and Week 96
|
|
|
Participant-reported treatment satisfaction
Tidsram: Week 48 and Week 96
|
HIV Treatment Satisfaction Questionnaire assesses participant satisfaction with the long-acting treatment. |
Week 48 and Week 96
|
|
Change in quality-of-life scores from baseline
Tidsram: Week 48 and Week 96
|
Quality of life will be assessed using the Veterans Rand 12-item Health Survey (VR-12). Scores range from 0 to 100, with higher scores indicating better health-related quality of life. |
Week 48 and Week 96
|
|
Change in Patient Health Questionnaire-9 (PHQ-9) scores from baseline
Tidsram: Week 48 and Week 96
|
Symptoms will be assessed using the Patient Health Questionnaire-9 (PHQ-9). Scores range from 0 to 27, with higher scores indicating more severe depressive symptoms. |
Week 48 and Week 96
|
|
Proportion of participants achieving and maintaining viral suppression without confirmed virologic failure among participants not requiring oral bridge therapy
Tidsram: Baseline through Week 48
|
Baseline through Week 48
|
|
|
Proportion of participants without oral bridge therapy with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
Tidsram: Week 48
|
Week 48
|
|
|
Proportion of participants without oral bridge therapy with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
Tidsram: Week 48
|
Week 48
|
|
|
Proportion of participants without oral bridge therapy with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
Tidsram: Week 48
|
Week 48
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- A5431
- 39159 (Annan identifierare: DAIDS-ES ID)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Individual participant data that underlie results in the publication after deidentification
Tidsram för IPD-delning
Beginning 3 months following publication and available throughout period of funding of the Advancing Clinical Therapeutics Globally (ACTG) by NIH
Kriterier för IPD Sharing Access
With whom? Researchers who provide a methodologically sound proposal for use of the data that is approved by the ACTG.
For what types of analyses? To achieve aims in the proposal approved by the ACTG.
By what mechanism will data be made available? Researchers may submit a request for access to data using the ACTG "Data Request" form at: https://actgnetwork.org/submit-a-proposal/. Researchers of approved proposals will need to sign an ACTG Data Use Agreement before receiving the data
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- SAV
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .